+Compare
ALPN
Stock ticker:
NASDAQ
AS OF
Aug 5 closing price
Price
$8.90
Change
+$0.06 (+0.68%)
Capitalization
269.92M

ALPN Price Prediction, Alpine Immune Sciences AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Aug 05, 2022

ALPN's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ALPN turned positive on August 04, 2022. Looking at past instances where ALPN's MACD turned positive, the stock continued to rise in 39 of 43 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 05, 2022. You may want to consider a long position or call options on ALPN as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ALPN moved above its 50-day moving average on August 03, 2022 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPN advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for ALPN crossed bearishly below the 50-day moving average on July 27, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALPN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALPN entered a downward trend on July 06, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.339) is normal, around the industry mean (26.217). P/E Ratio (0.000) is within average values for comparable stocks, (100.146). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.703). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (7.117) is also within normal values, averaging (316.522).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

ALPN is expected to report earnings to rise 50.00% to -37 cents per share on August 16

Alpine Immune Sciences ALPN Stock Earnings Reports
Q2'22
Est.
$-0.37
Q1'22
Missed
by $0.08
Q4'21
Missed
by $0.23
Q3'21
Missed
by $0.57
Q2'21
Missed
by $0.12
The last earnings report on May 12 showed earnings per share of -25 cents, missing the estimate of -16 cents. With 67.08K shares outstanding, the current market capitalization sits at 269.92M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX), Global Blood Therapeutics (NASDAQ:GBT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.83B. The market cap for tickers in the group ranges from 2.5K to 235.48B. NONOF holds the highest valuation in this group at 235.48B. The lowest valued company is IMUND at 2.5K.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 176%. For the same Industry, the average monthly price growth was 178%, and the average quarterly price growth was -16%. LABFF experienced the highest price growth at 170,233%, while OTIC experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -1% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 12 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a developer of immunotherapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
188 East Blaine Street
Phone
+1 206 788-4545
Employees
85
Web
https://www.alpineimmunesciences.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LHCAX17.510.18
+1.04%
Lord Abbett Health Care A
GQERX16.930.04
+0.24%
GQG Partners US Select Quality Eq R6
TMCTX43.710.07
+0.16%
Touchstone Mid Cap Z
MBBRX10.12-0.03
-0.30%
MassMutual Balanced R4
BERIX12.81-0.08
-0.62%
Carillon Chartwell Income Fund

ALPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPN has been loosely correlated with BEAM. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPN jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPN
1D Price
Change %
ALPN100%
+0.68%
BEAM - ALPN
50%
Loosely correlated
+0.87%
NTLA - ALPN
47%
Loosely correlated
-3.22%
SANA - ALPN
47%
Loosely correlated
+11.07%
REPL - ALPN
47%
Loosely correlated
+0.24%
IMVT - ALPN
47%
Loosely correlated
+8.68%
More